| 000 | 01842 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250518055536.0 | ||
| 264 | 0 | _c20200804 | |
| 008 | 202008s 0 0 eng d | ||
| 022 | _a1476-5551 | ||
| 024 | 7 |
_a10.1038/s41375-019-0559-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPott, Christiane | |
| 245 | 0 | 0 |
_aMRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. _h[electronic resource] |
| 260 |
_bLeukemia _c02 2020 |
||
| 300 |
_a522-532 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBendamustine Hydrochloride _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Follicular _xdrug therapy |
| 650 | 0 | 4 |
_aLymphoma, Non-Hodgkin _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm, Residual _xdrug therapy |
| 650 | 0 | 4 | _aProgression-Free Survival |
| 650 | 0 | 4 |
_aRituximab _xadministration & dosage |
| 700 | 1 | _aSehn, Laurie H | |
| 700 | 1 | _aBelada, David | |
| 700 | 1 | _aGribben, John | |
| 700 | 1 | _aHoster, Eva | |
| 700 | 1 | _aKahl, Brad | |
| 700 | 1 | _aKehden, Britta | |
| 700 | 1 | _aNicolas-Virelizier, Emmanuelle | |
| 700 | 1 | _aSpielewoy, Nathalie | |
| 700 | 1 | _aFingerle-Rowson, Guenter | |
| 700 | 1 | _aHarbron, Chris | |
| 700 | 1 | _aMundt, Kirsten | |
| 700 | 1 | _aWassner-Fritsch, Elisabeth | |
| 700 | 1 | _aCheson, Bruce D | |
| 773 | 0 |
_tLeukemia _gvol. 34 _gno. 2 _gp. 522-532 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/s41375-019-0559-9 _zAvailable from publisher's website |
| 999 |
_c30054725 _d30054725 |
||